PP.05.24: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES WEIGHT AND MARKERS OF VISCERAL ADIPOSITY IN TYPE 2 DIABETES. (June 2015)

• Record Type: Journal Article
• Authors: Neeland, I.J.; Mcguire, D.K.; Chilton, R.; Crowe, S.; Lund, S.S.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E.
• Is Part Of: Journal of hypertension. Volume 33(2015)Supplement 1
• Publication Date: 2015-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000467865.59059.cd
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Empagliflozin increases urinary glucose excretion and reduces blood pressure (BP) and body weight. We explored the impact of empagliflozin versus placebo on surrogate markers of visceral adiposity (VA) in patients with type 2 diabetes. Design and method: Using pooled data from 2477 patients with type 2 diabetes from four 24-week phase III randomised trials of empagliflozin 10 mg or 25 mg (n = 1652) versus placebo (n = 825) as monotherapy or add-on therapy (mean [SD] age 55.6 [10.2] years, HbA1c 8.0 [0.9]%, office SBP 129 [15] mmHg and BMI 28.7 [5.5] kg/m 2 ), we assessed changes from baseline in HbA1c, body weight, validated markers of VA (waist circumference [WC], index of central obesity [ICO; ratio WC/height], visceral adiposity index [VAI; VAImen: (WC/[39.68 + (1.88 × BMI)] × (TG/1.03) × (1.31/HDL)); VAIwomen: (WC/[36.58 + (1.89 × BMI)] × (TG/0.81) × (1.52/HDL)]), and changes in estimated total body fat (eTBF) using the YMCA-formula (eTBFmen: 100*[−98.42 + (4.15*WC) – (0.082*weight)]/weight; eTBFwomen:100*[−76.76 + (4.15*WC) – (0.082*weight)]/weight). Results: In placebo and empagliflozin groups, respectively, baseline mean weight was 78.0 and 78.9 kg, WC was 97.7 and 98.0 cm, ICO was 0.594 and 0.593, VAI was 2.7 and 2.9, and eTBF was 33.8 and 32.9%. At week 24, compared with placebo, empagliflozin significantly reduced HbA1c (mean [SE] difference: −0.65% [0.03]; p < 0.001), body weight (−1.9 [0.1] kg; p < 0.001), WC (−1.3 [0.2] cm; p < 0.001), ICO (−0.008 [0.001]; p < 0.001) and VAI (−0.4 [0.1]; p < 0.01) but not eTBF (−0.3 [0.2]%; p = 0.08). Conclusions: Empagliflozin may directly reduce VA and potentially alter TBF beyond its effects on glycaemia.